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Southern Africa is an important focal point of botanical and cultural diversity but only a few plant species have hitherto become fully commer-
cialised as medicinal products. In recent years there has been an upsurge in research and development activity, resulting in several new products
and new crops. In this review, more than 90 of the best-known and most promising indigenous South African plants are listed and subjectively
evaluated in the context of their potential for commercialisation as medicinal products for a variety of applications. The history of product devel-
opment relating to the following species is brieﬂy discussed and the plants and some of their products are illustrated: Agathosma betulina (buchu),
Aloe ferox (bitter aloe), Artemisia afra (African wormwood), Aspalathus linearis (rooibos tea), Bulbine frutescens (burn jelly plant); Cyclopia gen-
istoides (honeybush tea), Harpagophytum procumbens (devil's claw), Hoodia gordonii (hoodia, ghaap), Hypoxis hemerocallidea (“African pota-
to”), Lippia javanica (fever tea), Mesembryanthemum tortuosum (=Sceletium tortuosum) (kanna, kougoed), Pelargonium sidoides
(“Umckaloabo”), Siphonochilus aethiopicus (African ginger), Sutherlandia frutescens (=Lessertia frutescens) (cancer bush), Warburgia salutaris
(pepperbark tree) and Xysmalobium undulatum (“Uzara”). The main factors that are apparently responsible for failure or success will be highlight-
ed, especially the importance of marketing strategy, proof of concept and barriers to market entry.
© 2011 SAAB. Published by Elsevier B.V. All rights reserved.
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The first systematic account of the medicinal plants of South
Africa were published by Pappe (1847, 1850, 1854, 1857,
1862, 1868), who described all the most important traditional
herbal medicines known at the time. The Flora Capensis (a co-
lonial flora) started by Harvey and Sonder (1860, 1862, 1864)
included anecdotal information about the medicinal uses of sev-
eral species and was probably intended as a plant use catalogue
to facilitate the British imperial trade in plant products. A his-
torically important book on medicinal plants is that of Smith
(1888, revised in 1895) which provides insight into the most
popular traditional medicine of the Eastern Cape region at
that time. The Flora of South Africa published in six volumes
by Marloth (1913–1932) also included information about com-
mercially relevant plants. Marloth was a trained pharmacist
with a special interest in medicinal plants. An important mile-
stone in the documentation of medicinal plants was the detailed
and comprehensive work of Watt and Breyer-Brandwijk
(1962), “The Medicinal and Poisonous Plants of Southern and
Eastern Africa”, which is still regularly cited in scientific publi-
cations. Van Wyk et al. (1997) further conceptualised and
popularised the field of medicinal plants in South Africa with
the book entitled “Medicinal Plants of South Africa”, which in-
cluded short scientific monographs of 132 of the most popular
and widely used medicinal plants. An updated and expanded
edition, now including 150 monographs, is available (Van
Wyk et al., 2009). Van Wyk and Gericke (2000) presented de-
tailed information on a large number of medicinal plants in Part
2 of the book “People's Plants”, which includes chapters on
general medicines, tonic plants, mind and mood plants,
women's health, wounds, burns and skin conditions, dental
care, perfumes and repellents, and soaps and cosmetics. A com-
prehensive list of southern African medicinal plants (with liter-
ature references) is that of Arnold et al. (2002). Several other
books provided valuable information on a regional level, espe-
cially those on Zulu medicinal plants by Hutchings et al.
(1996), useful Namibian plants by Von Koenen (2001) and
Sotho medicinal plants by Moffett (2010). Especially relevant
in the context of new product development is the book editedby Diederichs (2006), entitled “Commercialising medicinal
plants. A South African guide”. The various chapters cover
many aspects of research and development, including sustain-
able harvesting, conservation, trade regulations, economics,
propagation, cultivation, chemistry and pharmacology, processing
and packaging, marketing, business development and benefit-
sharing.
The aim of this paper is to give a historical perspective on
the commercialisation of medicinal plants in South Africa, to
evaluate the progress that has been made and to highlight the
potential of the South African medicinal flora for future re-
search and development. A subjective evaluation of the com-
mercial potential of more than 90 indigenous species is
presented, together with brief reviews of a selection of 16 me-
dicinal plants that are of particular interest in new product
development.
2. The diversity of potentially useful medicinal plants in
South Africa
The indigenous biological resources of Africa and the com-
mercialisation of plants in Africa were reviewed by Geldenhuys
and Van Wyk (2002) and Okole and Odhav (2002). According
to the “African Plant Checklist and Database Project” (Klopper
et al., 2006), 50136 angiosperm taxa occur in Africa south of
the Sahara (32424 taxa in tropical Africa and 22755 taxa in
southern Africa). The last two numbers add up to 55179 but
the discrepancy is due to different taxonomic treatments in
the two regions. This diversity represents perhaps 20 to 25%
of the global total. The potential commercial importance of
this resource can be judged by the comprehensive list of Afri-
can medicinal plants (Neuwinger, 2000), where more than 5
400 medicinal plant taxa and over 16300 medicinal uses are
listed. This means that 10.8% of the African flora is known to
be used in traditional medicine. The corresponding statistic
for southern Africa is an estimated 3 000 species or 13.8% of
the flora (Van Wyk and Gericke, 2000) or the more exact
count of 2 942 species (administered to humans), representing
13.5% of the flora, presented by Arnold et al. (2002). These fig-
ures are based on an angiosperm species count of 21817 for
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review of commercialised medicinal plants by Van Wyk and
Wink (2004) indicated that 83 African medicinal plants have
been commercialised (as branded products) and that at best
only 14 southern African species can be considered to be par-
tially or fully commercialised compared to 336 species in
Europe, for example. The most valuable of all medicinal plants
may well be Aloe vera L. (of North African or perhaps Arabian
origin) — fresh Aloe vera gel products had an annual retail
value of approximately US$ 125 million in 2004 (Afolayan
and Adebola, 2006).
From the data given above it is clear that there is a huge po-
tential source of species, crops and products that are available
for basic and applied research, as well as new product develop-
ment. A list of the most promising indigenous South African
species is presented in Table 1, showing that at least 90 medic-
inal plants can be considered for further development and com-
mercialisation. Author citations for botanical species names are
given in Table 1 and are not repeated in the text.3. Historical perspectives on new herbal product development
in South Africa
A large number of medicinal plants are regularly sold as
crude, unprocessed drugs on traditional markets in various
parts of South Africa (Cunningham, 1988; Williams et al.,
1997; Mander, 1998; Von Ahlefeldt et al., 2003; Street et al.,
2008; see also Ndhlala et al. (in press). The volumes and market
value of these products are considerable. It has been estimated
by Mander (1998) that the total volume of medicinal products
traded annually in South Africa may exceed 20000 tonnes,
with a turnover of approximately US$ 60 million per year.
There is a general trend to develop and brand these traditional
products so that they resemble more closely those consumer
products that are sold as over-the-counter medicines and herbal
supplements. Some of the first products in these informal mar-
kets were produced by the company Impilo Drugs north of Dur-
ban. Examples are shown by Diederichs (2006) and Ndhlala
et al. (in press).
In contrast to the large diversity of products in informal mar-
kets, only a few indigenous plants have thus far been developed
for the formal market (health shops and pharmacies). These
products are available as processed and standardised materials
in modern packaging and in various branded dosage forms
such as teas, tinctures, tablets, capsules or ointments. The 16
South African traditional medicines that have been partly or
fully developed as commercial crops and products are shown
in alphabetical order in Fig. 1. These are Agathosma betulina,
Aloe ferox, Artemisia afra, Aspalathus linearis, Bulbine frutes-
cens, Cyclopia genistoides, Harpagophytum procumbens, Hoo-
dia gordonii, Hypoxis hemerocallidea, Lippia javanica,
Mesembryanthemum tortuosum (=Sceletium tortuosum), Pelar-
gonium sidoides, S. aethiopicus, S. frutescens (=Lessertia fru-
tescens), Warburgia salutaris and Xysmalobium undulatum.
These species are briefly discussed below, with emphasis on
their commercial history.The process of commercialisation in South Africa can be
divided into four phases:
(1) Historical phase. Old South African products, first com-
mercialised more than 100 years ago, which include
Agathosma spp., A. ferox, A. linearis, Cyclopia spp.,
H. procumbens, P. sidoides and X. undulatum. These
products are well known in the international trade and
most of them have a long track record of exports to European
countries.
(2) Bioprospecting phase. This phase involves the large-
scale, ethnobotanically-guided screening of species to
identify plants with commercial potential. This phase
started in the early 1960s, with the companies Noristan
and Smith-Kline Beecham, in collaboration with organic
chemists from the Council for Scientific and Industrial
Research (CSIR) and botanists from the National Botan-
ical Institute (National Herbarium) in Pretoria, as the
main role players. During this time a project on edible
plants was started at the National Food Research Institute
of the CSIR, which included the first work on Hoodia
species (Maharaj, 2009). When the Noristan project was
terminated, a large data base with confidential research
results was transferred to the University of Cape Town.
A bioprospecting project was started at the CSIR in
1993 and is still ongoing. More recently, there has been
several multi-institutional projects (involving the South
African National Biodiversity Institute and South African
Universities) to explore the commercial potential of me-
dicinal plants. Numerous scientific discoveries were
made during this phase, including the isolation of mona-
tin (a sweetener) from Sclerochiton ilicifolius (Vleggaar
et al., 1992) and the discovery of P57 (an appetite sup-
pressant) in H. gordonii (Van Heerden et al., 1998). Pio-
neering work on H. hemerocallidea also dates from this
period, including the very first clinical study on an indig-
enous medicinal plant. The commercial history of
Hypoxis (and subsequent “immune system boosters” de-
rived from it) was reviewed by Drewes et al. (2008).
(3) Commercialisation phase. This phase started in the mid
1990s with research and development aimed at producing
branded health care products from well-known and wide-
ly used indigenous medicinal plants. A feature of this
phase was the development of several new crops, based
on the consideration that large-scale commercial develop-
ment may not be sustainable if the raw materials are taken
from nature. The projects and products were not based on
the results of bioprospecting, but focused on the most
popular South African traditional medicines that were al-
ready widely traded in informal markets or extensively
used as traditional household remedies. The health bene-
fits of the plant species were already in the public domain
for a long time (in most cases for at least a century). The
logic of this approach is clear — why look for “new”
products when the best ones have already been identified
through centuries of trial and error? Plants developed into
branded products during this phase include A. afra,
Table 1
Indigenous South African plant species of historic, current or potential importance in the formulation of commercial herbal medicines. Species which are partly or fully commercialised are shown in bold. (Subjective
importance rating: +++ = high, ++ = average, + = low or none).
Species; family; common name(s)
(partially or fully commercialised species
are indicated in bold)
Plant parts used and medicinal use(s):
(ro)ot (incl. rhizome, tuber or bulb); (st)em;
(le)af; (ﬂ)ower; (fr)uit; (se)ed; (ex)udate;
(es)sential oil; (oil); (ed)ible oil/seed oil/ﬁxed oil;
leaf parenchyma (gel)
Acacia karroo Hayne; Fabaceae; sweet thorn ba and le+ (diarrhoea), ex++ (emollient for conjunctivitis
and haemorrhage, as pharmaceutical aid in solid formulations)
Adansonia digitata L.; Bombacaceae; baobab fr++ (fever, diarrhoea), ba++ (urinary disorders, mild diarrhoea), le++ (fever)
Agathosma betulina (P.J.Bergius) Pillans; Rutaceae; round leaf buchu le+++, es+++ (bitter tonic, digestive, diuretic, flavourant, externally for wounds)
Agathosma crenulata (L.) Pillans; Rutaceae; oval leaf buchu le++, es++ (bitter tonic, digestive, diuretic, externally for wounds)
Alepidea amatymbica Eckl. & Zeyh.; Apiaceae; lesoko, ikhathazo ro+++ (chest ailments, colds, influenza)
Alepidea cordifolia B.-E. Van Wyk; Apiaceae; lesoko, ikhathazo ro+++ (chest ailments, colds, influenza)
Aloe arborescens Mill.; Xanthorrhoeaceae; kranz aloe, Japan aloe gel+++ (topical uses, health drinks)
Aloe ferox Mill.; Xanthorrhoeaceae; bitter aloe, Cape aloe ex+++ (laxative medicines, bitter tonics), gel+++ (topical uses, health drinks)
Aloe marlothii A.Berger; Xanthorrhoeaceae; mountain aloe (Natal aloes) ex++ (laxative medicines, ethnoveterinary uses)
Artemisia afra Jacq. ex Willd.; Asteraceae; African wormwood, wilde-als le+++ (bitter tonic, digestive, stomach pain, fever), es+++ (inhalant, aromatherapy)
Aspalathus linearis (Burm.f.) R.Dahlgren; Fabaceae; rooibos tea st and le+++ (health drinks, anti-ageing?, anti-carcinogenic?)
Aspalathus pendula R.Dahlgren; Fabaceae; golden tea st and le+++ (health drinks, source of rutin)
Asparagus laricinus Burch. (and other spp.); Asparagaceae; wild asparagus, katdoring ro++ (diuretic, tonic, various uses)
Athrixia phylicoides DC.; Asteraceae; bush tea, Zulu tea st, le and ro+++ (various uses, health drinks?)
Ballota africana (L.) Benth.; Lamiaceae; kattekruid le+++ (infusions, tinctures: various uses, antispasmodic? sedative?)
Bulbine frutescens (L.) Willd.; Xanthorrhoeaceae; ibhucu leaf gel+++ (topical uses, digestive tonic drinks)
Carpobrotus edulis (L.) L.Bolus; Mesembryanthemaceae; common sour fig le++ (astringent, gargle for sore throat), fr++ (appetite suppressant)
Centella asiatica (L.) Urb.; Apiaceae; pennywort le+++ (mainly topical uses, wound healing)
Chironia baccifera L.; Gentianaceae; Christmas berry, aambeibos st and le+++ (bitter tonic, appetite stimulant)
Citrillus lanatus (Thunb.) Matsum. & Nakai; Cucurbitaceae; tsamma melon se++ (oil for cosmetic use)
Conyza scabrida DC.; Asteraceae; oondbos le+++ (inflammation, colds, fever)
Colenema album (Thunb.) Bartl. & H.L.Wendl.; C. juniperinum Sond. (and other spp.); confetti bush, fever bush le+++ (colds and fever), es++ (topical uses, aromatherapy)
Cyclopia genistoides (L.) R.Br. (and other spp.); Fabaceae; honeybush tea st and le+++ (health drinks)
Dicoma anomala Sond.; Asteraceae; hloenya, umuna, maagbossie ro+or le+++ (colds and fever, stomach ailments, general medicine)
Dicoma capensis Less.; Asteraceae; koorsbossie, wilde karmedik ro and le+++ (colds and fever, general medicine)
Dodonaea viscosa Jacq. var. angustifolia (L.f.) Benth.; Sapindaceae; ysterhout, sandolien le+++ (colds and fever, venotonic, general medicine)
Elephantorrhiza elephantina (Burch.) Skeels; Fabaceae; intolwane, elandboontjie ro+++ (antioxidant, skin ailments, diarrhoea, perforated ulcers,
prostate hypertrophy, male pattern baldness)
Elytropappus rhinocerotis (L.f.) Less.; Asteraceae; renosterbos st and le+ (indigestion, dyspepsia, ulcers, stomach cancer,
fumigant against influenza, appetite stimulant, bitter tonic)
Eriocephalus africanus L. (and other spp.); Asteraceae; Cape snowbush, kapokbos le+++ (bitter tonic, digestive, stomach pain, fever), es+++ (inhalant, aromatherapy)
Eriocephalus punctulatus DC.; Asteraceae; Cape chamomile le+++ (bitter tonic, digestive, stomach pain, fever), es+++ (inhalant, aromatherapy)
Euclea natalensis A.DC. (and other spp.); Ebenaceae; Natal guarri ro++ (bronchitis, chest ailments, pleurisy, asthma, urinary tract infections, toothache,
headache, toothbrush sticks/mouth rinses)
Eucomis autumnalis (Mill.) Chitt.; Asparagaceae (Hyacinthaceae); pineapple flower ro++ (anti-inflammatory, urinary diseases, stomach ache, diarrhoea, enema for
low back pain and healing of fractures)
Garuleum bipinnatum (Thunb.)Less.; Asteraceae; slanghoutjie ro++ (expectorant, diaphoretic, diuretic)
Galenia africana L.; Aizoaceae; kraalbos, geelbos le++ (topical products to treat skin ailments and infections)
Geranium incanum Burm.f. (and other spp.); Geraniaceae; vrouebossie, bergtee le+ (health tea, bitter tonic, anti-diarrhoeal)
(continued on next page)
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Table 1 (continued)
Species; family; common name(s)
(partially or fully commercialised species
are indicated in bold)
Plant parts used and medicinal use(s):
(ro)ot (incl. rhizome, tuber or bulb); (st)em;
(le)af; (ﬂ)ower; (fr)uit; (se)ed; (ex)udate;
(es)sential oil; (oil); (ed)ible oil/seed oil/ﬁxed oil;
leaf parenchyma (gel)
Gethyllis spp.; Amaryllidaceae; kukumakranka fr+++ (digestives, tonics)
Gunnera perpensa L.; Gunneraceae; river pumpkin, gobo, ughobo ro++ (uterotonic, stomach ailments, menstrual pain, rheumatic fever, topical application
for wounds and psoriasis)
Harpagophytum procumbens (Burch.) DC. ex Meisn.; Pedaliaceae; devil's claw ro+++ (arthritis, painful joints, dyspepsia and loss of appetite, topical application
for wounds)
Helichrysum nudifolium (L.) Less.; Asteraceae; hottentotsteebossie le+ (colds, chest ailments)
Helichrysum odoratissimum (L.) Sweet; Asteraceae; imphepho, Nguni incense, everlastings le+++ (ritual incense, sedative), es+++ (inhalant, aromatherapy)
Heteromorpha arborescens (Spreng.) Cham. & Schltdl.; Apiaceae; parsley tree es++ (headache, inhalant, aromatherapy?)
Heteropyxis natalensis Harv.; Myrtaceae; lavender tree le++ (colds, weaning, roots for nose bleeds and bleeding gums, menorrhagia) ,
es++ (aromatherapy, topical products)
Hoodia gordonii (Masson) Sweet ex Decne. (and other spp.); Apocynaceae; ghaap, ghôba, hoodia st++ (appetite suppressant)
Hypoxis hemerocallidea Fisch. & Avé-Lall.; Hypoxidaceae; inkomfe, “African potato” ro++ (traditional tonic, benign prostate hyperplasia )
Kigelia africana (Lam.) Benth.; Bignoniaceae; sausage tree fr++ (skin care, cosmetics)
Leonotis leonurus (L.) R.Br. (and other spp.); Lamiaceae; wild dagga le+++ (coughs, colds, influenza, asthma, bronchitis, ethnoveterinary uses)
Lessertia frutescens: see Sutherlandia frutescens
Leysera gnaphalodes (L.) L.; Asteraceae; duinetee, hongertee st and le+++ (health tea, coughs, appetite stimulant)
Lippia javanica (Burm.f.) Spreng.; Verbenaceae; fever tea le+++ (health tea, fever, cough, colds, bronchitis, influenza)
Lippia scaberrima Sond.; Verbenaceae; mosukujane le+++ (health tea, fever, cough, colds, bronchitis, influenza)
Mentha longifolia (L.) Huds.; Lamiaceae; wild mint, ballerja le+++ (headache, indigestion, fever, cough, colds, bronchitis, influenza, insomnia), es++
(aromatherapy)
Mesembryanthemum tortuosum L. [=Sceletium tortuosum (L.) N.E.Br.]; Mesembryanthemaceae; sceletium,
kanna, channa, kougoed
le+++ (sedative, hypnotic)
Monsonia angustifolia E.Mey. ex A.Rich; Geraniaceae; mokorotswana st and le++ (diarrhoea, low libido)
Muraltia spinosa (L.) F.Forest. & J.C.Manning [=Nylandtia spinosa (L.) Dumort.]; Polygalaceae; cargoe,
skilpadbessie
st and le++ (digestive drinks, appetite stimulant, bitter tonic)
Myrothamnus flabellifolius Welw.; Myrothamnaceae; resurrection plant, bergboegoe le+++ (health drinks, oral hygiene, gingivitis, topical products), es+++ (topical antiseptic,
aromatherapy)
Ocotea bullata (Burch.) Baill.; Lauraceae; stinkwood ba++ (headache, stomach ailments), es++ (aromatherapy)
Olea europaea L. subsp. africana (Mill.) P.S.Green; Oleaceae; wild olive le+++ (bitter tonic, cardiotonic, hypotensive, diuretic)
Oncosiphon suffruticosum (L.) Källersjö (and other spp.); Asteraceae; stinkkruid st and le++ (digestive tonic, stomachic, colds, fever, respiratory ailments, topically for skin ailments
and inflammation)
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Osmitopsis asteriscoides (P.J.Bergius) Less.; Asteraceae; bels, belskruie le+++ (respiratory ailments, colds, fever, topically for inflammation and wounds), es+++ (ointments,
aromatherapy)
Pelargonium graveolens L'Hér. (and other spp.); Geraniaceae; rose geranium le+++ (colds, respiratory ailments, topically as e ollient for wound healing), es+++ (aromatherapy)
Pelargonium sidoides DC.; Geraniaceae; rabas, “Umckaloabo” ro+++ (colic, dysentery, colds and influenza, bro chitis)
Pelargonium reniforme Curtis.; Geraniaceae; rabas ro++ (colic, dysentery, colds and influenza, bron hitis)
Pittosporum viridiflorum Sims; Pittosporaceae; cheesewood ba+ (stomach ailments, fever)
Plumbago auriculata Lam.; Plumbaginaceae; plumbago ro, ste and le+ (antispasmodic, coughs, headache
Prunus africana (Hook.f.) Kalkman; Rosaceae; red stinkwood ba+ (benign prostate hyperplasia)
Salvia africana-caerulea L. (and other spp.); Lamiaceae; bloublomsalie, wild sage le+++ (respiratory and digestive ailments)
Sansevieria hyacinthoides (L.) Druce (and other spp.); Asparagaceae; piles root ro and le++ (topical uses, ear infection, haemorr ids, skin ulcers)
Scabiosa columbaria L.; Caprifoliaceae; wild scabious le and ro++ (colic, heartburn)
Sceletium tortuosum: see Mesembryanthemum tortuosum
Sclerocarya birrea (A.Rich.) Hochst.; Anacardiaceae; marula se(oil)+++ (skin care), ba++ (stomach ailments, ver, diabetes)
Securidaca longepedunculata Fresen.; Polygalaceae; violet tree ro+ (chest complains, rheumatism, various other ses)
Senecio serratuloides DC.; Asteraceae; two days, insukumbili le++ (wound-healing ointments)
Siphonochilus aethiopicus (Schweinf.) B.L.Burtt; Zingiberaceae; African ginger ro+++ (colds, cough, influenza, hysteria, p n, asthma, dysmenorrhoea, anti-inflammatory,
bronchodilatory)
Sutherlandia frutescens (L.) R.Br.; Fabaceae; cancer bush le+++ (adaptogen, tonic, anti-diabetic, cancer pr hylaxis?)
Syzygium cordatum Hochst. ex C.Krauss.; Myrtaceae; water berry, umdoni ba+ (respiratory ailments, stomach complaints)
Tarchonanthus camphoratus L. (sensu lato); Asteraceae; wild camphor bush le+ (respiratory and stomach ailments), es+++ (i alant, aromatherapy)
Tetradenia riparia (Hochst.) Codd; Lamiaceae; iboza, ginger bush le++ (respiratory ailments), es+++ (inhalant, aro atherapy)
Teucrium africanum Thunb., T. trifidum Retz.; Lamiaceae; katjiedrieblaar le++ (indigestion, colds, fever, general tonic)
Trichilia dregeana Sond., T. emetica Vahl; Meliaceae; umkhuhlu, Natal mahogany se(oil)+++ (skin care, rheumatism)
Tulbaghia alliacea L.f.; Alliaceae; wild garlic le++ (fever, colds)
Tulbaghia capensis L.; Alliaceae; Cape wild garlic le++ (fever, colds)
Tulbaghia violacea Harv.; Alliaceae; wild garlic le+++ (fever, colds)
Typha capensis (Rohrb.) N.E.Br.; Typhaceae; bulrush ro+ (venotonic, male tonic)
Valeriana capensis Thunb.; Caprifoliaceae; Cape valerian ro++ (asthma, insomnia, hysteria, nervous disord rs)
Vernonia oligocephala (DC.) Sch.Bip. ex Walp.; Asteraceae; groenamara le+ (stomachic, bitter tonic)
Viscum capense L.f., Viscaceae; Cape mistletoe; litjiestee st+++ (health tea, tonic drinks)
Warburgia salutaris (Bertol.f.) Chiov.; Canellaceae; pepperbark tree ba+, le+++ (coughs, colds, chest complaints, ora nd oesophageal thrush, cystitis, natural antibiotic)
Withania somnifera (L.) Dunal; Solanaceae; Indian ginseng, geneesblaarbossie ro+++ (adaptogen, tonic, sedative), le+++ (woun -healing ointments)
Ximenia americana L., X. caffra Sond.; Olacaceae; sourplum se (oil)+++ (skin care)
Xysmalobium undulatum (L.) Aiton f.; Apocynaceae; ishongwe, “uzara” ro+++ (anti-diarrhoeal, spasmolytic, wound-heal g)
Zanthoxylum capense (Thunb.) Harv.; Rutaceae; small knobwood ro, le, fr++ (dental plaque, oral rinses)
Ziziphus mucronata Willd.; Rhamnaceae; buffalo-thorn, mokgalo le, ro++ (general tonic)
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S. frutescens and W. salutaris. Amongst the earliest prod-
ucts were L. javanica and L. scaberrima herbal teas1A 1B
2A 2B
3A
4A 4B
A
Fig. 1. South African medicinal plants of current commercial interest and examples of p
leaves; 1D, traditional tincture; 1E, tincture developed by South African Druggist in 1
lump/aloe bitters; 2D, cut leaf showing gel and yellow juice; 2E, example of containe
tonic containing aloe lump); 3, Artemisia afra (3A, plantation, planted 1995; 3B, leave
developed by Phyto Nova in 2002); 4, Aspalathus linearis (4A, plantation; 4B, plant o
tea; 4E, modern rooibos product). 5, Bulbine frutescens (5A, plantation; 5B, flowering
Cyclopia species (6A, C. genistoides; 6B, C. intermedia; 6C, C. subternata; 6D, honeyb
experimental plantation, 1995; 7B, leaves and flowers; 7C, fruit and product — sliced
plants; 8C, stems of various Hoodia species; 8D, example of modern product). 9, Hy
plants; 9D, corms; 9E, tincture); 10, medicinal teas (10A, Leonotis leonurus flowers; 1
nica leaves and flowers; 10E, Mentha longifolia leaves and flowers); 11, M. tortuosu
leaves; 11C, flowering plant; 11D, traditional product; 11E, tablets developed by Phy
12B, flowering plant; 12C, flowers; 12D, roots; 12E, tincture). 13, Siphonochilus aethio
developed by Phyto Nova in 2000); 14, Sutherlandia frutescens (14A, plantation, plan
totypes and products – developed by Phyto Nova in 2000); 15, Warburgia salutaris (1
leaves, developed by Phyto Nova in 2000); 16, Xysmalobium undulatum (16A, comme
tographs: all by B.-E. Van Wyk.produced by the Veld Foods initiative in Botswana (ca.
1995) and the Healer's Choice range of branded products
developed by South African Druggists (now incorporated1C 1D 1E
2C
2D
2E
2F
3B 3C 3D
4C 4D 4E
2G
roducts. 1, Agathosma betulina (1A, plantation, planted ca. 1993; 1B, flowers; 1C,
996); 2, Aloe ferox (2A, plantation, planted 1976; 2B, flowering plant; 2C, aloe
r with aloe bitters; 2F, an example of an aloe gel drink; 2G, example of a bitter
s and flower heads; 3C, tincture developed by SA Druggists in 1996; 3D, tablets,
f the commercial Red tea type; 4C, leaves and flowers; 4D, red and green rooibos
plant; 5C, flowers; 5D, leaves showing gel; 5E, commercial product, ca. 2002); 6,
ush tea; 6E, example of modern packaging); 7,Harpagophytum procumbens (7A,
and dried secondary tubers; 7D, tincture); 8, Hoodia gordonii (8A,B, flowering
poxis hemerocallidea (9A, experimental plantation, ca. 2000; 9B, 9C, flowering
0B, Leysera gnaphalodes flowers; 10C, Lippia javanica plant; 10D, Lippia java-
m (11A, experimental plantation, planted 1996; 11B, stems, showing scletonised
to Nova in 2000); 12, Pelargonium sidoides (12A, first plantation, planted 1995;
picus (13A, plantation; 13B, flowering plant; 13C, rhizome and roots; 13D, tablets
ted 2002; 14B, flowering and fruiting plant; 14C, dried leaves; 14D, tablets – pro-
5A, tree; 15B, fruit; 15C, leaves and flowers; 15D, bark; 15E, tablets made from
rcial plantation; 16B, flowering plant; 16C, leaves and flowers; 16D, roots). Pho-
5A 5B 5C 5D 5E
6A 6B 6C 6D 6E
7A 7B 7C 7D
8A 8B 8C 8D
B
Fig. 1 (continued).
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ed a tincture made from low-thujone clones of Artemisa
afra. The first research and development of M. tortuosum
(=Sceletium tortuosum) also occurred during this period
(Gericke and Van Wyk, 1997). The branded tinctures
produced in the SA Druggists era served as role models
and numerous similar tinctures (small and large scale)
are now available. Another noteworthy effort to produce
new crops and new herbal health care products is that
of the company Phyto Nova (Pty) Ltd, responsible for
the first branded products developed from M. tortuosum,
S. aethiopicus, S. frutescens and W. salutaris. The last-
mentioned was the origin of the concept of plant part re-
placement, i.e. the replacement of bark with chemically
similar leaves, as a conservation measure. These products
were developed as tablets and some are still availableunder the Phyto Nova Natural Medicines brand (a new
name given to the company when it was taken over by
Thebe Medicare in 2005). Some of the prototypes and
first branded products developed by Phyto Nova are
shown in Fig. 1. This phase has seen an unprecedented
increase in the number of scientific publications and cita-
tions in patents (details are given in Van Wyk, 2008a and
Makunga et al., 2008). A scopus search on 25 April 2008
showed that the number of citations in publications of the
above-mentioned 16 commercial species increased from
a total of 102 up to the year 1995, to 469 in the period
1996 to 2005, whilst the number of citations in patents
rose from 72 to 438 in the corresponding periods (data
from Table 1 in Van Wyk, 2008a).
(4) Regulated bioprospecting phase. This phase started in
2008 when the regulations of the National Environmental
9A 9B 9C 9D 9E
10A 10B 10C 10D 10E
11A 11B 11C 11D
12A 12B
12C
12E
11E
12D
C
Fig. 1 (continued).
820 B.-E. Van Wyk / South African Journal of Botany 77 (2011) 812–829Management: Biodiversity Act of 2004 (NEMBA) came
into effect on the 1st of April 2008. The Act attempts to
ensure the equitable distribution of the benefits to be de-
rived from the commercialisation of the South African
flora. The implications of benefit sharing in practice
have been discussed by several authors in the book edited
by Denzil Phillips International (2009). Whilst the aims
of the Act are laudable, the implementation of the regula-
tions is impractical and may inadvertently discourage
rather than encourage innovation in this potentially im-
portant sector of the economy. A review of relevant leg-
islation and regulations can be found elsewhere in this
issue (Myburgh, in press).
A very brief summary of the commercial history and pub-
lished information for each of 16 commercially importantmedicinal plants of South Africa (see Fig. 1 and Table 1) is pre-
sented below. Monographs of these plants and general informa-
tion about them can be found in Watt and Breyer-Brandwijk
(1962), Hutchings et al. (1996), Van Wyk et al. (1997, 2009),
Van Wyk and Gericke (2000), Von Ahlefeldt et al. (2003),
Van Wyk and Wink (2004), Diederichs (2006), Van Wyk
(2008a), Brendler et al. (2010) and Gurib-Fakim et al. (2010).
A broad review of the ethnobotany, basic biology, taxonomy,
biosystematics, genetics, chemistry and biological activity of
most of the species was provided by Van Wyk (2008a), so
that these aspects are not discussed in detail here. Also exclud-
ed are pan-African species which have been commercialised
elsewhere (or with manufacturing based on raw material sup-
plies from other African countries), such as Adansonia digitata,
Centella asiatica, Kigelia africana, Prunus africana, Trichilia
emetica and Withania somnifera.
13A 13B 13C 13D
14A 14B 14C 14D
15A 15B 15C 15D
16A 16B 16C 16D
15E
D
Fig. 1 (continued).
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Round leaf buchu is endemic to the Cederburg region of South
Africa and is an important plant in the Khoi-San tradition. It has
been wild-harvested at least since 1820 and cultivated since the
1970s or perhaps even earlier (Fig. 1, 1A). Recent efforts in
crop development have resulted in buchu now being a viable op-
tion for small-scale farming (although producer prices have fluc-
tuated wildly in recent years). Recently growers experienced
severe losses, ascribed to a soilborne disease (Bezuidenhout
et al., 2010). Tinctures of buchu (“buchu brandy”, Fig. 1, 1D
and medicinal products, Fig. 1, 1E) have a great reputation as
general health tonics, stomachics, aromatic bitters, diuretics and
mild urinary antiseptics (Van Wyk and Gericke, 2000). The
major volatile compounds of round leaf buchu are isomenthoneand diosphenol (Kaiser et al., 1975; Posthumus et al., 1996;
Collins et al., 1996; Moolla and Viljoen, 2008), which are
not only responsible for the distinctive flavour (not unlike cassis)
but probably also for antispasmodic, antiseptic and diuretic ac-
tivities (Wichtl and Bisset, 2000, Lis-Balchin et al., 2001;
Moolla and Viljoen, 2008). The closely related oval leaf
buchu (A. crenulata), as well as hybrids between the two species,
are less desirable due to high levels of pulegone, a potentially
harmful substance.
3.2. A. ferox (Xanthorrhoeaceae) — bitter aloe, Cape aloe
(Fig. 1, 2A to G)
A. ferox has a very long history of use in southern Africa, as
is evidenced by a San rock painting (Reynolds 1950) depicting
822 B.-E. Van Wyk / South African Journal of Botany 77 (2011) 812–829humans interacting with aloes. At current levels of demand,
wild-crafting can be done without serious damage to natural
populations (Newton and Vaughan, 1996). The first A. ferox
plantation (6 ha) was established by Dr Tewis Muller on the
farm Vinklaagte near Albertinia in 1976 (Fig. 1, 2A). Several
other plantations have recently been established (e.g. 19 ha on
the farm Tierfontein near Albertinia, in February 2008). By
growing the plants in rows on open flat terrain, the harvesting
operation becomes more efficient (because of easy access to
the plants by both people and vehicles) thus reducing overall
production costs and allowing for irrigation (by tractor-drawn
water carts) during droughts so as to ensure a steady supply
of raw materials. The bitter yellow leaf exudate (Fig. 1, 2D)
is tapped by stacking the cut leaves around a hollow in the
ground (lined with an animal skin or nowadays plastic sheet-
ing), allowing the liquid to collect in the hollow. The exudate
is boiled on open fires to reduce the water content, so that it so-
lidifies to form a dark brown or black, glass-like substance
known as aloe lump or Cape aloes (Fig. 1, 2C). This laxative
medicine has been exported to Europe since 1761 (Marloth,
1913–1932; Kruger and Beyers, 1977; Robertson, 1979).
Aloin (syn. barbaloin), an anthrone-C-glycoside, is the main
laxative compound in aloe lump (Van Wyk et al., 1995). Annu-
al exports in recent years amounted to ca. 350 tonnes (Knapp,
2006). The aloe lump is sold as is (Fig. 1, 2E) or tinctures con-
taining aloe lump are used as traditional bitter tonics and sto-
machics (Fig. 1, 2F, 2G), reputed to also have anti-arthritic
and anti-inflammatory properties (Newall et al., 1996;
Blumenthal et al., 1998; Wichtl and Bisset, 2000; ESCOP,
2003). Nowadays the non-bitter, leaf parenchyma gel, obtained
as “jelly” through a patented process (O'Brien et al., in press)
and used to produce gel drinks, is the most popular product
for the local industry (Fig. 1, 2F). A wide range of cosmetics
and skin care products are also based on A. ferox gel. Another
potential use of the gel is as a pharmaceutical excipient in
novel drug delivery systems from renewable sources (Fischer
et al., 2000). The work of the Aloe Council of South Africa
(a non-profit company founded in 2003) has led to the develop-
ment of a South African national standard for aloe raw mate-
rials, published in 2007 (Standards South Africa, 2007).
There are important differences between the gels of A. ferox
and A. vera — the South African gel product has polysaccha-
rides of the arabinogalactan and rhamnogalacturonan types
and it lacks acetylated sugars (Mabusela et al., 1990; O'Brien
et al., in press). The quality control criteria for A. vera gel are
therefore not applicable to A. ferox. There are opportunities to
develop new products for human and animal health care, not
only from A. ferox but also from other species such as A.
arborescens and A. marlothii. Grace et al. (2008, in press) pro-
vided reviews of the traditional uses of Aloe species in southern
Africa.
3.3. A. afra (Asteraceae)— African wormwood (Fig. 1, 3A to F)
African wormwood (wildeals in Afrikaans, lengana in Sotho
and umhlonyane in Xhosa and Zulu) is one of the most popular
and widely used traditional medicines in southern and easternAfrica (from Cape Town to Addis Abeba). The aromatic leaves
are used for the treatment of a wide range of ailments (Dykman,
1908; Watt and Breyer-Brandwijk, 1962; Hutchings et al.,
1996; Van Wyk et al., 1997; Neuwinger, 2000; Von Koenen,
2001; see also Bora and Sharma, 2011). It is the most important
bitter tonic and appetite stimulant of Cape herbal medicine
(Dykman, 1908; Thring and Weitz, 2006; Rood, 2008, Van
Wyk 2008b) and is commonly taken for respiratory ailments
and stomach pain. The essential oil of A. afra is exceptionally
variable (Graven et al., 1990; Lawrence, 1996; Viljoen et al.,
2006) but often contains 1,8-cineole (=eucalyptol), α-thujone,
β-thujone, camphor and borneol as main monoterpenoids, to-
gether with chrysanthenyl acetate and other sesquiterpenoids.
It is considered to be a useful substitute for armoise oil,
which is produced from A. vulgaris L. and used in perfumes
and as flavouring agent. Mukinda and Syce (2007) studied
acute and chronic toxicity of A. afra essential oil (both quite
low) but the level of thujone (which is a toxic compound) in
the experimental material was not reported.
The plant is cultivated in home gardens as a medicinal herb
and rooted cuttings are available from retail nurseries in South
Africa. The first experimental plantings were made by Prof.
Earle Graven at Fort Hare University (see Graven et al.,
1990) in the late 1980s as part of a still ongoing research project
on essential oils and the first commercial plantation at Gouda in
the Western Cape Province of South Africa in 1995 (Fig. 1, 3A)
as part of the South African Druggists project. The first com-
mercial products based on low-thujone material were devel-
oped under the brand names of Healer's Choice in 1996 (as
a tincture, Fig. 1, 3C) and Phyto Nova in 2002 (as tablets,
Fig. 1, 3D).
3.4. A. linearis (Fabaceae) — rooibos tea (Fig. 1, 4A to E)
Rooibos tea has become a popular herbal tea with a growing
reputation of having important health benefits, including anti-
spasmodic, anti-oxidant, anti-ageing and anti-eczema activities
(Watt and Breyer-Brandwijk, 1962; Van Wyk et al., 1997,
2009; Burger and Wachter, 1998; Van Wyk and Gericke,
2000; Van Wyk and Wink, 2004; Joubert et al., 2008; Joubert
and De Beer, 2011). It has been used as a milk substitute for in-
fants suffering from colic and has become popular as a health
drink because of the absence of caffeine or other stimulants. It
is one of the most successful and important of the indigenous
industries. Annual production from plantations has reached
20000 tonnes per annum and export volumes now exceed
local consumption. The modest beginnings and early growth
of the industry is described by Anonymous (1975), where men-
tion is made of the first tea-makers of the Cederberg (of Khoi-
San descent), the first commercialisation by Benjamin Ginsberg
in 1904, the pioneering crop development efforts of Louis Lei-
poldt, P. le Fras Nortier and Oloff Bergh (and later also James
Van Putten) and the background history of the establishment
of the Rooibos Tea Control Board in 1954, as a single-channel
marketing system to try and stabilise the wildly fluctuating sup-
ply and demand for rooibos tea. Amongst the early brands were
Cederberg, Cedro, Clantee, Eleven O'Clock, Freshpak,
823B.-E. Van Wyk / South African Journal of Botany 77 (2011) 812–829Grandiflora, Laager and Union. The chalcone aspalathin is the
main phenolic compound (1 mg per g in fermented and up to
50 mg per g in unfermented tea) and is used for quality control
(Joubert et al., 2008; Joubert and De Beer, 2011). Only the so-
called Red type or Rocklands type is cultivated, but there is a
renewed interest in harvesting some of the wild types for
niche markets and Fair Trade networks (Van Wyk et al.,
1997, 2009; Raynolds and Ngcwangu, 2010; Hawkins et al.,
2011). Noteworthy recent innovations are the development of
green and espresso rooibos tea (Fig. 1, 4D, E). Detailed reviews
of rooibos tea are those of Joubert et al. (2008) and especially
Joubert and De Beer (2011).
3.5. B. frutescens (Xanthorrhoeaceae) — burn jelly plant,
ibhucu (Fig. 1, 5A to E)
The fresh leaf gel of B. frutescens and several other spe-
cies are traditionally used topically to stop bleeding and to
treat burns, cracked lips, cuts, grazes, itches, mosquito
bites, rashes, ringworm, sores, wounds and herpes (Smith,
1895; Watt and Breyer-Brandwijk 1962; Roberts, 1990;
Van Wyk et al. 1997, 2009; Van Wyk and Gericke 2000;
Rood, 2008). A recent in vivo study has validated the tradi-
tional use of B. frutescens and B. natalensis leaf gel in the
treatment of wounds (Pather et al., 2011). A tea made from
the fresh whole plant (including roots) of B. abyssinica is
taken by women to treat back pain, bladder and vaginal
problems, cough, infertility and unspecified ailments (Van
Wyk et al., 2008). Infusions of the roots of several Bulbine
species are taken to treat blood disorders, convulsions, diabe-
tes, diarrhoea, nausea (vomiting), rheumatism, urinary com-
plaints and venereal diseases (Watt and Breyer-Brandwijk,
1962; Van Wyk et al., 1997, 2009; Felhaber and Mayeng,
1997; Van Wyk and Gericke, 2000; Rood, 2008). The
main commercial interest is in the leaf gel, developed as
branded products since 1995, for example as Montagu Muse-
um Bulbine Crème (Fig. 1, 5E) and the BulbAloe range de-
veloped by J. Levine in 2004. A patented product
(Widgerow and Chait, 1998) comprising microporous paper
tape impregnated with a combination of bulbine gel (12.5
to 25% but preferable 20%) with pantheol and asiaticoside
was shown (in a clinical study of nearly 300 patients) to en-
hance wound healing and hasten scar maturation. The heal-
ing effects are likely to be due to polysaccharides and/or
glycoproteins in the leaf gel, as well as hydrating effects
(Widgerow et al., 2000).
3.6. C. genistoides (Fabaceae)— honeybush tea (Fig. 1, 6A to E)
A comprehensive review of this important health drink is
presented by Joubert et al. (in press). Honeybush tea lacks caf-
feine and has proven health benefits, including antioxidant,
antimutagenic, anticarcinogenic and oestrogenic activity. The
original product dates back to at least the middle of the eigh-
teenth century (Pappe, 1847) and was made from C. genistoides
(Marloth, 1913–1932) (Fig. 1, 6A). However, C. intermedia E.
Mey. (Fig. 1, 6B) and C. subternata Vogel (Fig. 1, 6C) are alsoimportant sources of this tea, known respectively as mountain
tea and vlei tea. The first branded products date back to the
1960s (e.g. Caspa Cyclopia Tea) (Joubert et al., in press). The
industry is rapidly growing as a result of crop development
by De Lange (1997), as well as improved processing and phar-
macological studies, as summarised by Joubert et al. (in press).
Important basic scientific information was contributed by De
Nysschen et al. (1996), who first discovered and identified
mangiferin as the major phenolic compound in honeybush
tea, and Schutte (1997), who resolved the complicated infrage-
neric taxonomy of the genus Cyclopia. Honeybush tea has be-
come very popular in recent years and the industry is poised
for substantial growth (Joubert et al., in press).
3.7. H. procumbens (Pedaliaceae) — devil's claw (Fig. 1, 7A
to D)
Devil's claw is widely distributed in the Kalahari region of
southern Africa (Angola, Botswana, Namibia, South Africa
and Zimbabwe) and has become a popular herbal medicine to
treat arthritis, painful joints, dyspepsia and loss of appetite
(Blumenthal et al., 1998; Newall et al., 1996; Wichtl and
Bisset, 2000; Wegener, 2000; ESCOP, 2003; Van Wyk and
Wink, 2004). Mild analgesic and anti-inflammatory properties
have been reported in several clinical studies, reviewed by
Wegener (2000), Chrubasik et al. (2003), Gagnier et al.
(2004) and De Silva et al. (2011). The activity has been as-
cribed to iridoid glycosides — mainly harpagoside (0.5% to
3%), with smaller amounts of harpagide and procumbide, but
total extracts are more active than the individual iridoids. The
commercial history of devil's claw is poorly recorded but can
be traced back to at least ca. 1907, when G.H. Mehnert started
exporting dried tubers from Namibia to Germany (Cole, 2009).
It is interesting that the plant is depicted in rock engravings in
the Northern Cape Province of South Africa, indicating that
the plant may have been important to Khoi-San people since
ancient times. One of the first experimental plantations (1 ha)
was established at Gouda in the Western Cape Province of
South Africa in 1995 (Fig. 1, 7A). A review of the harvesting
and export of this internationally well-known herbal product
(mainly from Namibia) is presented by Stewart and Cole
(2005) and Cole (2009), who highlighted the problems associ-
ated with benefit sharing when a plant is distributed across na-
tional boundaries.
3.8. H. gordonii (Apocynaceae) — hoodia, ghaap (Fig. 1,
8A to D)
Hoodia species and related plants of the family Apocyna-
ceae are important traditional food sources of the Khoi-San
people, first explicitly recorded by Marloth in 1932 as being
useful in suppressing appetite (Marloth, 1913–1932). The his-
tory of research and development work on hoodia was
reviewed by Maharaj (2009). The appetite-suppressant effect
has been ascribed to a pregnane compound known as P57
(Van Heerden et al., 1998; Van Heerden, 2008) but there is as
yet no published human clinical data to support the claim that
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of scientific information on efficacy and appropriate therapeutic
doses, hoodia products have become popular all over the world
(Jayawardane, 2011). The agreement reached between the
CSIR and the San community (Maharaj, 2009) is one of the
first examples of compensation of a local community for the
benefits derived from the commercialisation of indigenous
knowledge. A comprehensive review of H. gordonii was re-
cently presented by Vermaak et al. (2011).
3.9. H. hemerocallidea (Hypoxidaceae)— star flower, inkomfe,
“African potato” (Fig. 1, 9A–E)
This plant has become famous as a result of millions of
rands spent on research and development since 1967, when
Hypoxis phytosterols were first developed into a branded
product (Harzol®) by an entrepreneur from Johannesburg (R.
W. Liebenberg), who successfully marketed and sold it in Ger-
many for the treatment of benign prostate hypertrophy (Drewes
et al., 2008). A commercial preparation initially based onHypoxis
phytosterols (later on industrial sources) and claimed to have im-
mune-stimulating effects was a huge market success in South Af-
rica (Drewes and Horn, 1999; Drewes et al., 2008). The main
active compounds of Hypoxis include rooperol (Drewes et al.,
1984) which has patented anti-cancer activity (Drewes and Lie-
benberg, 1983) and phytosterols, which are still associated with
over-the-counter immune-boosting products (Pegel 1973,
1997). Some in vitro evidence was published for the claimed
immune-stimulant effects (Bouic et al., 1996). Extracts of the
corms of Hypoxis (Fig. 1, 9D) are ingredients of an ever diversify-
ing range of products used as anti-oxidants, anti-inflammatories,
anti-diabetics and anti-convulsants (Drewes et al., 2008; see also
the review by Owira and Ojewole, 2009).
3.10. L. javanica (Verbenaceae) — fever tea (Fig. 1, 10C to D)
Wild-harvested leaves of L. javanica and L. scaberrima have
been used since the mid 1990s in branded infusions (herbal
teas) to treat bronchitis, colds, coughs and fever. The plants are
also traditionally used against numerous other ailments (Watt
and Breyer-Brandwijk, 1962; Hutchings et al., 1996; Van Wyk
et al., 1997, 2009; Van Wyk and Gericke, 2000). The traditional
uses, chemistry and pharmacology were reviewed by Pascual et
al. (2001). The essential oil of L. javanica is highly variable
and five distinct chemotypes, each with its own main compound
(myrcenone, carvone, piperitenone, ipsenone or linalool) were
described by Viljoen et al. (2005). Leaves of Lippia scaberrima
are also used as tea but the main components of the oil are car-
vone, 1,8-cineole and limonene (Combrinck et al., 2006). Stan-
dardised chemotypes may be suitable for use as flavour
components in herbal teas, in addition to their reputed medicinal
benefits. Other species that have potential as ingredients of herbal
teas (individually or in combination with other species) include
Leonotis leonurus (Fig. 1, 10A), Leysera gnaphalodes (Fig. 1,
10B) and Mentha longifolia (Fig. 1, 10E), all of which have a
long history of traditional use as medicinal teas in southern Africa
(Van Wyk and Gericke, 2000).3.11. M. tortuosum [syn. Sceletium tortuosum]
(Mesembryanthemaceae)— sceletium, kanna, kougoed (Fig. 1,
11A to E)
Kougoed, kanna or sceletium is a traditional masticatory and
sedative of the Nama people of South Africa, first recorded in
detail by Simon van der Stel (1685) under the name “Channa”.
In a molecular systematic study (Klak et al., 2007), Sceletium
and other genera were formally subsumed under the genus Me-
sembryanthemum. The uses and properties have been described
by Watt and Breyer-Brandwijk (1962), Watt (1967), Smith et
al. (1996), Van Wyk and Gericke (2000), Van Wyk and Wink
(2004), Gericke and Viljoen (2008) and Van Wyk et al.
(2009). It is interesting to note that the first experimental plant-
ings (Fig. 1, 11A) were made in 1996, more than 300 years
after Van der Stel (1685) first suggested that profit could be
made from growing and trading with channa. The activity of
the plant and the traditional product (Fig. 1, 11B–D) is ascribed
to serotonin reuptake-inhibiting alkaloids, of which mesembr-
ine is the main compound (Gericke and Van Wyk, 1997). The
first tablets containing powdered whole plants were produced
by Phyto Nova in 2000 (Fig. 1, 11E). A benefit-sharing agree-
ment was recently signed between HGH Pharmaceuticals and
the South African San Council, who in turn entered into an
agreement with the Nama communities of Kamiesberg in Na-
maqualand to share financial benefits that may result from com-
mercialisation. Research and development work is currently
underway to create what may become an important and com-
mercially successful herbal sedative for international markets.
3.12. P. sidoides (Geraniaceae) — rooirabas, “Umckaloabo”
(Fig. 1, 12A to D)
The interesting commercial history of this important plant,
first developed and marketed in England in 1898 (for the treat-
ment of tuberculosis), was described by Brendler and Van Wyk
(2008). It is now mainly used for the treatment of bronchitis.
Crop development started near Wellington in the Western
Cape Province of South Africa in 1995 (Feiter, 2009), when
the first plantations (Fig. 1, 12A) were established. Since the
early 1990s, a tincture made from the tuberous roots (Fig. 1,
12C,D) has become one of the most successful phytomedicines
in the world, with annual sales in Germany alone exceeding €
80 million. The medicinal properties are associated with cou-
marins, including umckalin and 5,6,7-methoxycoumarin
(Kolodziej and Kayser, 1998; Kayser et al., 2001). Details of
the commercial history, botany, chemistry, pharmacology and
clinical studies can be found in the review of Brendler and
Van Wyk (2008), whilst recent developments related to intel-
lectual property rights are presented by Feiter (2009) and
Myburgh (in press).
3.13. S. aethiopicus (Zingiberaceae) — African ginger (Fig. 1,
13A to D)
This plant is widely distributed in tropical Africa and the rhi-
zomes and roots are very important and popular traditional
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headache and malaria (Watt and Breyer-Brandwijk, 1962; Van
Wyk et al., 1997, 2009; Van Wyk and Gericke, 2000; Crouch et
al., 2000; Van Wyk and Wink, 2004; Van Wyk, 2008a). Pio-
neering research on the cultivation and tissue culture propaga-
tion of S. aethiopicus were done during the early 1990s by
G. Nichols (at the Silverglen Municipal Nursery near Durban
— Fig. 1, 13A) and J.N. Eloff (at the Kirstenbosch Research
Centre in Cape Town). It is now commercially cultivated on a
small scale at several locations in South Africa. The first brand-
ed products (tablets made from freeze-dried rhizomes and
roots) were marketed by Phyto Nova in 2000 (Fig. 1, 13C,D).
The major chemical constituents are sesquiterpenoids of the
furanoid type (Van Wyk et al., 1997; Holzapfel et al., 2002;
Viljoen et al., 2002) and diarylheptanoids (Van Wyk et al.,
2009). Research and development at the CSIR is ongoing (see
brief review by Van Wyk, 2008a).
3.14. S. frutescens [syn. Lessertia frutescens] (Fabaceae) —
cancer bush, sutherlandia (Fig. 1, 14A to D)
Cancer bush is traditionally used in southern Africa as a
tonic and adaptogen (known in Sesotho as Musapelo) to allevi-
ate stress and anxiety (Moteetee and Van Wyk, 2007). Pub-
lished and unpublished traditional uses and anecdotes are
summarised in a review by Van Wyk and Albrecht (2008).
These include asthma, cancer (prevention and treatment),
chronic bronchitis, colds, cough, diabetes, dysentery, fever,
gastritis, heartburn, heart failure, indigestion, influenza, kidney
and liver ailments, oesophagitis, peptic ulcers, poor appetite,
rheumatism, unspecified wasting diseases and urinary tract in-
fections. It has received special attention because of anecdotes
suggesting dramatic improvements in the quality of life in
HIV/AIDS patients and a reduction in the muscle-wasting (ca-
chexia) effect of AIDS. A safety study done by the Medical Re-
search Council of South Africa (Seier et al., 2002) and a clinical
(phase I) study (Johnson et al., 2007) showed no signs of toxic-
ity or side effects. The leaves contain a diversity of chemical
compounds (reviewed by Van Wyk and Albrecht, 2008), in-
cluding pinitol, triterpenoid saponins, flavonoids and amino
acids (such as L-canavanine and GABA), to which various bio-
logical activities have been ascribed. Commercial plantations
were established in the late 1990s (e.g. at Sannieshof in the
North-West Province, Fig. 1, 14A). The first branded products
were tablets made from powdered leaves of a selected chemo-
type that became known as the SU1 type — the protypes and
products dating from 2000 and marketed by Phyto Nova are
shown in Fig. 1, 14D.
3.15. W. salutaris (Canellaceae) — pepperbark tree (Fig. 1,
15A to E)
The pepperbark tree is one of the most important and popu-
lar traditional medicines of tropical Africa. The bark (Fig. 1,
15D) is widely used to treat abdominal pain, cancer, constipa-
tion, colds, coughs, fever, headache, influenza, malaria, rheu-
matism and venereal diseases (Van Wyk and Gericke, 2000;Van Wyk et al., 2009). The tree has become rare and endan-
gered in South Africa as a result of excessive harvesting of
bark, so that chemically similar leaves (with the same pungent
taste as the bark) were used to produce the first branded product
(tablets), marketed by Phyto Nova in 2000 as a natural antibiot-
ic to treat oral and oesophageal thrush (Fig. 1, 15E). The con-
servation and cultivation of W. salutaris were initiated by the
company HL& H (now Mondi Forests), who started a living
gene bank of about 3000 trees at their White River Nursery.
Using expertise in the rooting of Eucalyptus cuttings, a large
number of trees were propagated for distribution in 1996,
when W. salutaris was chosen as South Africa's “Tree of the
Year”. By the year 2000, Mr Rodger Stewart has established
a small plantation on a farm north of Durban, KwaZulu-Natal,
using horticultural experience gained in commercial tea planta-
tions. As a result, freeze-dried leaves and bark are now avail-
able in small commercial quantities. Recently, a new product
was developed by Phyto Nova Natural Medicines (from
freeze-dried Warburgia leaf) to treat cystitis. The bark and
leaves contain drimane sesquiterpenoids (Mashimbye et al.,
1999), including warburganal, mukaadial, salutarisolide, poly-
godial and isopolygodial, as well as muzigadial (Rabe and
Van Staden, 2000).
3.16. X. undulatum (Apocynaceae)— Uzara, ishongwe (Fig. 1,
16A to D)
The roots of X. undulatum are important in traditional med-
icine in South Africa. It is used to treat abscesses, afterbirth
cramps, colic, diarrhoea, headache, hysteria, stomach cramps
and wounds, as recorded by Watt (1935), Watt and Breyer-
Brandwijk (1962), Pujol (1990), Hutchings and Van Staden
(1994), Hutchings et al. (1996), Van Wyk et al. (1997, 2009)
and Von Koenen (2001). It also has a long history of commer-
cial use and has been cultivated in South Africa (near Pretoria)
since 1904 (Fig. 1, 16A). Extracts were introduced into the Ger-
man pharmaceutical market in 1909 (or 1911, according to
Ghorbani et al., 1997) and marketed (under the name
“Uzara”) for the treatment of non-specific, acute diarrhoea.
The roots contain uzarin and xysmalorin as major cardenolide
glycosides (Ghorbani et al., 1997), to which the inhibition of in-
testinal motility is ascribed.
4. Species with commercial potential as herbal products
As shown in Table 1, there are numerous species that stand
out as having exceptional potential for the development of new
phytomedicines, dietary supplements or general tonics. Some
are also suitable for new ethnoveterinary products, although
this application is not specifically dealt with here (see McGaw
and Eloff, 2008). The evaluation of species in Table 1 is some-
what subjective, but the following aspects are important:
(1) The species must be suitable for cultivation (or be abundant
in nature to allow wild-crafting — i.e. sustainable harvesting
from the wild); (2) it must have a well-recorded history of tra-
ditional use (preferably in more than one traditional healing cul-
ture); (3) it must be regularly used, with no evidence of side
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remedies for the particular indication it is being developed/
marketed for and (5) there must be a potential demand for the
product. There may be a demand for more sophisticated dosage
forms and standardised products within the culture where it is
well known, or a new demand may be created around compelling
evidence of safety and efficacy in the historical track record of the
species, preferably with interesting ethnobotanical information to
support the marketing efforts.
The list in Table 1 includes several well-known and commer-
cially important species that have for unknown reason never re-
ceived much attention in South Africa, such as Aloe
arborescens, Centella asiatica, Kigelia africana, Pelargonium
graveolens and Withania somnifera. Also listed are several
plants that appear to have considerable potential, including
Alepidea amatymbica, Aloe marlothii, Aspalathus pendula, Bal-
lota africana, Chironia baccifera, Colenema album, Dicoma
anomala, D. capensis, Dodonaea viscosa, Eriocephalus africa-
nus, E. punctulatus, Gethyllis species, Gunnera perpensa,
Helichrysum odoratissimum, Heteropyxis natalensis, Leonotis
leonurus, Leysera gnaphalodes, Mentha longifolia, Myrotham-
nus flabellifolius, Olea europaea subsp. africana, Osmitopsis
asteriscoides, Salvia africana-caerulea, Sclerocarya birrea,
Tarchonanthus camphoratus, Tetradenia riparia, Teucrium trifi-
dum, Trichilia dregeana, T. emetica, Tulbaghia violacea, Vis-
cum capense, Ximenia americana and X. caffra.
5. Discussion
5.1. Proof of concept and scientific data
Scientific evidence to substantiate medicinal claims appears
to be the most important limiting factor in the development of
indigenous herbal products. Traditional uses may be a good
starting point in product development but is unlikely to lead
to sustainable commercial success in the long run. Examples
that come to mind are H. hemerocallidea, Aloe vera and H. gor-
donii. Hypoxis was the subject of numerous studies in the 1970s
and formed the basis of a lucrative trade in so-called “immune-
stimulants” but as yet there is no convincing in vivo evidence
published in peer-reviewed journals. Aloe gel health drinks
are perhaps the best example of a major international herbal
product that still lacks convincing clinical evidence of thera-
peutic benefits. The almost complete absence of published clin-
ical studies is especially noteworthy when the enormous annual
turnover of this industry is considered. (Perhaps no-one wants
to spoil a good marketing story with inconvenient facts?).
Weight loss products are often purely market-driven and Hoo-
dia appears to be no exception. The lack of reliable published
clinical evidence on the therapeutic dose and its efficacy as ap-
petite suppressant does not seem to be regarded as a serious
concern and there are still numerous Hoodia-containing prod-
ucts available on the international market.
The main stimulus for marketing success of herbal products
appears to be proof of concept in the form of human trials. The
commercial success of two of the most famous and valuable in-
digenous species can be related to clinical evidence of efficacyin the form of double-blind, placebo-controlled studies: H. pro-
cumbens became internationally known after the first clinical
studies were conducted in France and Germany in the 1960s;
P. sidoides became the basis of a very lucrative over-the-
counter medicine only after several clinical studies (sum-
marised in Brendler and Van Wyk, 2008). The recent boom
in the rooibos tea industry may at least partly be ascribed to a
growing body of scientific evidence indicating important health
benefits. Clinical evidence in the form of post-marketing sur-
veillance or double-blind, placebo-controlled studies may pay
healthy dividends in the long run, despite the large financial in-
puts required for this type of research. A good example is the
marketing success achieved with P. sidoides. However, this de-
pends on the product being developed. No company will spend
a lot of money on clinical research to develop an anti-diarrhoeal
as there are already many such products available.
5.2. Intellectual property rights
Legislation aimed at protecting the intellectual property
rights of indigenous communities, despite good intentions, is
likely to become an important new barrier to entry in commer-
cialisation and product development. Recent experiences
(Denzil Phillips International, 2009), have shown that some of
the regulations are impractical and that prospective developers
are subjected to excessive bureaucracy. See also the review
by Myburgh (in press) in this issue.
5.3. The importance of marketing
Sustainable commercial success appears to be achieved only
after many years of investment and marketing. The few indige-
nous plants that have become important commercial crops and
products all have a very long history of crop and product devel-
opment, with large amounts of money spent on marketing over
many years. These include A. betulina (since 1820), A. ferox
(since 1761), A. linearis (since 1904), C. genistoides (since
1847; branded since the 1960s), H. procumbens (since ca.
1907), P. sidoides (since 1898) and X. undulatum (since
1909). In 2002, it was estimated that the establishment of a
new brand of herbal medicine in South Africa would cost at
least R 12 million rands or ca. € 1.2 million (Louis Schutte,
S.A. Natural Products, personal communication, 2002). Multi-
level marketing, the backbone of the enormous Aloe vera in-
dustry in the USA, has in recent years proven to be a highly
successful strategy in South Africa and may become increas-
ingly important in response to a very competitive retail market.
There is no doubt that opportunities still exist for market-driven
development projects based on those indigenous medicinal
plant species listed in Table 1.
6. Conclusions
The exceptionally diverse South African flora comprises nu-
merous species that can be developed as exciting new products
(including herbal medicines and other health care products,
herbal teas and functional foods). There is an urgent need to
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build local capacity in this field and to implement measures to
counteract the negative perceptions and practical difficulties as-
sociated with restrictive new regulations. The development of a
successful new product is a complicated process that requires
hard work, technical skills, substantial investment and innova-
tive marketing, sustained over long periods. The pioneers
involved in this process often gain nothing except the satisfac-
tion that they have created opportunities for the next generation
of skillfull entrepreneurs to achieve market success. It is hoped
that inspired and talented individuals will be allowed the free-
dom to maximise the opportunities presented by the rich diver-
sity of the South African flora by developing innovative
products in order to create new marketing opportunities in
local and international markets, and to find new ways of gener-
ating wealth for the benefit of all.Acknowledgements
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